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Veno�s thromboembolism �VTE�� is seven fold in-
creased in patients with malignancy when compared to 
patients not affected by solid t�mors [�]. Malignancy 
ind�ces an acq�ired thrombophilic state [�]; therefore�� 
in almost all cancer patients a s�b clinical activation of 
blood coag�lation takes place�� even witho�t symptoms 
of thrombosis. The hypercoag�lable state in cancer 
arises mostly from the capacity of t�mo�r cells to ex-
press and release specific procoag�lant activities like 
cancer procoag�lant �CPA�� and tiss�e factor �TF�� and 
to interact with the host’s endotheli�m�� platelets and 
monocytes-macrophages ind�cing a prothrombotic 
phenotype within these cells [3]. The association be-
tween malignancy and VTE s�ch as the relationship 
between t�mor growth and coag�lation activation has 
been known since Tro�ssea�’s time [4]. Nowadays it is 
evident that the coag�lation system plays an important 
role in the biology of malignant t�mors: the activation 
of haemostasis ind�ces a contin�o�s formation and 
removal of fibrin which mediates the adhesion of t�mor 
cells to endotheli�m facilitating their migration thro�gh 
the tiss�es and contrib�ting to t�mor progression [�]. Re-
cent st�dies have revealed a nonhaemostatic role of TF 
in generation of coag�lation proteases and s�bseq�ent 
activation of proteases activated receptors �PARs�� on 
vasc�lar cells. This TF dependent signaling contrib�tes 
to a variety of biological processes incl�ding inflamma-
tion�� angiogenesis and metastasis [6]. The prothrombotic 
state of cancer patients is enhanced by therape�tic in-
terventions�� s�ch as s�rgery�� chemotherapy�� hormone 
therapy�� radiotherapy and it is related to disease stage 
and to the site of origin of the primary t�mor: patients 
with haematological cancer have the highest risk of VTE�� 
followed by those with l�ng and gastrointestinal cancers 
[��� 6]. Therefore q�antification of the magnit�de of the 
thrombotic risk associated with malignancy and anti-
cancer therapy is essential to �se anticoag�lant dr�gs 
which selectively interfere with haemostatic mechanisms 
probably protecting patients both from VTE and from 
t�mor progression [��]. St�dies on haemostatic system in 
cancer patients show an increase in clotting factors lev-
els�� markers of thrombin and fibrin generation�� fibrynolitic 
proteins and thrombocytosis [8]. However�� none of the 
coag�lation activation markers has any predictive val�e 
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Background: Quantification of the magnitude of thrombotic risk associated with malignancy and with anti-cancer therapy is indispensable 
to use anticoagulant drugs which selectively interfere with haemostatic mechanisms protecting patients from venous thromboembolism 
(VTE) and probably from tumor progression. However, none of activation coagulation markers has any predictive value for the occurrence 
of the thrombotic events in one individual patient. Current clotting methods can’t reveal the overall dynamic clot formation; in contrast 
thromboelastographic methods specifically assess overall coagulation kinetics and its strength in whole blood. Aim: Objective of study 
was to evaluate if the activation of coagulation as eventually revealed by ROTEM® thromboelastometry could assess an hypercoagulable 
state in surgical neoplastic patients. Patients and Methods: Fifty consecutive patients with carcinoma of the digestive tract in preoperative 
period (23 M, 27 F aging 61.5 (45–79 years) and 147 healthy subjects (71 M, 76 F) were studied. A recent thromboelastometric method 
based on thrombelastography after Hartert was employed. Measurements were performed on ROTEM Coagulation Analyzer. The con-
tinuous coagulation data from 50 min course were transformed into dynamic velocity profiles of WB clot formation. Results: Standard 
parameters (CT, CFT, MCF) of cancer patients were similar to controls. CT (in cancer patients): females 50 s (38.3–58.7), males 50 s 
(42–71.2) vs 51 s (42–59), p = 0.1210 / 53 s (42–74.8), p = 0.1975 (in controls). CFT (in cancer patients): females 72 s (32- 92.4), 
males 80 s (50.2- 128.7) vs 78 s (62–100), p = 0.0128 / 80 s (59–124.4), p = 0.9384 (in controls). MCF (in cancer patients): females 
70 mm (59.9–82.5), males 63 mm (56–73.7) vs 69 mm (59–95.8), p = 0.9911 / 69 mm (53.6–90), p = 0.0135 (in controls). Females 
showed a higher MaxVel when compared to males. The MaxVel was increased in cancer patients: females 19 mm /100 s (14.3–49.5) 
males 18 mm / 100 s (11–27) vs 15 mm 100 s (11.8–22), p < 0.001 / 13 mm / 100 s (10–21.8), p < 0.001 in controls .The t-MaxVel was 
shortened in cancer patients: females 65 s (48.6–112.8), males 81 s (50.1–135.9) vs 115 s (56.8–166), p <0.001 / 115 s (59.8–180.8), 
p = 0.0002 in controls. The AUC was increased in cancer patients: females 6451 mm 100 (5511–8148), males 5984 mm 100 (5119-
6899) vs 5778 mm 100 (4998–6655), p < 0.001 / 5662 mm 100 (4704–6385), p = 0.0105. Conclusion: Unlike other assays measuring 
variations in a single component during coagulation, the thrombelastographic method records a profile of real-time continuous WB clot 
formation, and may provide extensive informations on haemostasis in neoplastic patients before surgery. 
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formation time�� CP� �� cancer procoa��ulant�� C�� �� clottin�� time�� 
MC� �� maximum clot firmness�� P�Rs �� proteases activated re-
ceptors�� ��� �� tissue factor�� V��E �� venous thromboembolism.
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for the occ�rrence of the thrombotic events in one in-
divid�al patient [�]. Since reliable methods�� that co�ld 
have a higher predictive val�e for thrombosis risk�� are 
needed�� o�r aim is to get better informations eval�ating 
the profile of extended time coag�lation analysis. Th�s�� 
the investigation of coag�lation dynamics in whole blood 
co�ld�� in o�r opinion�� disclose an abnormal pattern in 
cancer patients�� especially in those at increased throm-
botic risk. C�rrent laboratory clotting techniq�es cannot 
f�lly identify s�bjects with an increased thromboembolic 
risk: their performance in plasma and the addition of 
b�ffered sol�tions limit their relevance to overall dynamic 
clot formation in whole blood [��]. In contrast ROTEM 
thrombelastometry specifically assess overall coag�la-
tion kinetics and strength in whole blood�� providing a 
global assessment of haemostatic f�nction [��].
Therefore the aim of this st�dy was to investi-
gate whether an hypercoag�lable state�� revealed by 
ROTEM�� can be an important variable to eval�ate 
the coag�lation derangements in patients affected by 
cancer of the digestive tract.
maTerials and meThods 
Patients. �� patients with histologically confirmed 
solid cancer of the digestive tract were st�died. 
�3 were male�� ��� were female and all aging 6�.� �4��
��� years��. The criteria for incl�sion in the st�dy have 
been: patients with a carcinoma of the digestive tract 
witho�t history of VTE who were candidate for s�rgery. 
�4�� healthy s�bjects ���� M�� ��6 F�� selected on the basis 
of sex and age were enrolled in o�r st�dy as control 
gro�p. The st�dy was approved by Ethics Committee 
of the Instit�te. Informed consent was collected from 
all participants.
Sample collection. Blood samples were drawn be-
tween 8 am and � am�� after �� h of fasting. The blood 
�nine vol�mes�� was placed in t�bes with �.��� M of 
trisodi�m citrate �one vol�me�� �ntil analysis.
Test procedure. A recent thromboelastometric 
method �ROTEM®; Pentapharm Ltd�� M�nich�� Ger-
many; distrib�ted in Italy by Dasit�� Milano���� based on 
the thrombelastography after Hartert��was employed 
[��]. Meas�rements were performed on a ROTEM 
Coag�lation Analyzer. Citrated blood samples were 
recalcified with CaCl� �star-TEM®�� reagent�� and ac-
tivated with tiss�e thromboplastin from rabbit brain 
�ex-TEM�� reagent�� for monitoring the extrinsic system. 
The ROTEM® analysis determines the onset of the 
coag�lation process: clotting time �CT��; the kinetics of 
clotting formation and stability: clotting formation time 
�CFT�� and maxim�m clot firmness �MCF�� �Fig. ��� a��. 
The ROTEM® software also calc�lates the novel pa-
rameters according to Sorensen [�4] s�ch as MaxVel�� 
t-MaxVel�� AUC by data derived from the ROTEM c�rve. 
MaxVel describes the maxim�m velocity of the clot 
formation. It is the maxim�m rate of clot formation�� the 
maxim�m of the one derivative c�rve. 
t-MaxVel describes the time from start of the mea-
s�rement till MaxVel �maxim�m of the one derivative�� 
is reached. It is a parameter similar to CT.
AUC describes the area �nder the velocity �one 
derivative�� c�rve and is eq�ivalent to MCF in a c�rve 
where the test had been r�n till MCF had been reached 
[�4] �Fig. ��� b��.
fig. 1, a. Standard thrombelastographic tracking �CT�� CFT�� MCF��
fig. 1, b. ROTEM c�rve displayed by ROTEM Gamma software 
Velocity profile�� the first derivative of the ROTEM tracking: maxi-
m�m velocity �MaxVel���� time to maxim�m velocity �t-MaxVel���� 
area �nder c�rve �AUC�� from Sorensen [�3]
Statistical analysis. Statistical significance of the 
differences of val�es between patients and the healthy 
controls was calc�lated by the Mann — Whitney U test. 
The differences were considered statistically signifi-
cant only for p-val�es less �.�� �Tables ��� ���. 
Table 1. RO��EM standard parameters in neoplastic patients and in 
healthy reference subjects
Healthy 
Males Median 5P 95P p value
Patients 
Males Median 5P 95P
C�� 53 42 74,8 0.1975 C�� 50 42 71,2
C��� 80 59 122,4 0.9384 C��� 80 50,2 128,7
MC� 69 53,6 90 0.0135 MC� 63 56 73,7
Healthy 
�emales 
Patients 
�emales
  
C�� 51 42 59 0.1210 C�� 50 38,3 58,7
C��� 78 62 100 0.0128 C��� 72 32 92,4
MC� 69 59 95,8 0.9911 MC� 70 59,9 82,5
Medians and reference ran��e (5��95% percentile ) for controls and pa-
tients.
Table 2. RO��EM velocity parameters in neoplastic patients and in healthy 
reference subjects
Healthy 
Males Median 5P 95P p value 
Patient 
Males Median P5 P95
MaxV 13 10 21,8 0.001 MaxV 18 11 27
MaxV-t 115 59.8 180.8 0.0002 MaxV-t 81 50.1 135.9
��C 5662 4703.6 6385 0.0105 ��C 5984 5118.7 6899.2
Healthy 
�emales
Patients 
�emales
  
MaxV 15 11.8 22 0.001 MaxV 19 14.3 49.5
MaxV-t 115 56.8 166 0.001 MaxV-t 65 48.6 112.8
��C 5778 4998 6655 0.001 ��C 6451 5514.8 8148.4
Medians and reference ran��e (5��95% percentile) for controls and for patients.
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resulTs 
Standard parameters of ROTEM �CT�� CFT�� MCF�� were 
not different in cancer patients as compared to controls. 
CT �in cancer patients��: females �� s �38.3��8.������ males 
�� s �4�����.��� vs �� s �4�������� p = �.����/�3 s �4����4.8���� 
p = �.����� �in controls��. CFT �in cancer patients��: females 
��� s �3����.4���� males 8� s ���.����8.���� vs ��8 s �6��������� 
p = �.���8 / 8� s ������4.4���� p = �.�384 �in controls��. 
MCF �in cancer patients��: females ��� mm ���.��8�.����� 
males 63 mm ��6���3.���� vs 6� mm ������.8���� p = �.����/ 
6� mm ��3.6������� p = �.��3� �in controls��. The analysis 
showed: an increase in MCF in male controls as compared 
to patients and a shorter CFT in female patients than in 
controls �Table ���. The contin�o�s coag�lation data from 
a �� min-time co�rse were transformed into dynamic 
velocity profiles of WB clot formation [�4] �Fig. ���. 
fig. 2, a, b, c, d, e, f. �box plot��: medians and reference range 
�����% percentile�� of MaxVel�� t-Max Vel�� AUC for controls and 
patients
There were higher MaxVel in female controls 
as compared to male controls. The res�lts were in 
accordance with earlier st�dies [��]. The ROTEM® 
velocity parameters res�lted significantly different in 
patients when compared to the parameters of healthy 
s�bjects. The MaxVel was increased �cancer patients��: 
females �� mm ���/ s ��4.3�4�.����� males �8 mm 
���/ s ��������� vs �� mm ���/s ���.8������� p <�.���/�3 
mm ���/s ������.8���� p < �.��� �controls��. The t-
MaxVel was shortened �cancer patients��: females 
6� s �48.6� ���.8���� males 8� s ���.���3�.��� vs ��� s 
��6.8��66���� p < �.���/��� s ���.8��8�.8���� p = �.���� 
�controls��. The AUC was increased �cancer patients��: 
females 64�� mm ��� ������8�48���� males ��84 mm 
��� ������68���� vs �����8 mm ��� �4��8�66������ p < 
�.���/�66� mm ��� �4���4�638����� p = �.���� �con-
trols�� �Table ���.
discussion
Reliable markers and methods to predict thrombo-
tic risk are essential to clinical management�� especially 
for high- risk patients�� i. e.�� cancer patients �ndergoing 
therape�tic interventions. Most laboratory tests act�-
ally �sed for st�dying haemostasis are performed on 
platelet-poor plasma with clotting [��] or chromogenic 
[�6] end points. Nowadays�� thanks to a better �nder-
standing of the role of platelets�� le�kocytes and eryth-
rocytes in the clotting process�� to eval�ate thrombin 
generation d�ring blood coag�lation has become the 
best approach in order to assess the global complex 
process [���]. However�� whereas thrombin generation 
tests are diffic�lt to perform in real time clinical prac-
tice [�8]�� thrombelastographic recording of the whole 
blood coag�lation process is anticipated to indirectly 
reflect the co�rse of thrombin generation .The classical 
thrombelastography prod�ces a profile of the overall 
rheological changes occ�rring d�ring coag�lation 
and in the past it has been prevalently �sed to assist 
clinicians in the control of after-s�rgery bleeding. 
A newer modification of classical thrombelastography 
is thromboelastometry �ROTEM®���� which avoids some 
technical limitations of the traditional method�� s�ch as 
sensitivity to vibrations or mechanical shocks. ROTEM 
�ses a ball bearing system for power transd�ction 
which makes it easily transportable and less s�scep-
tible to mechanical stress�� movement and vibration. 
F�rthermore�� the activation of the samples accelerates 
the meas�rement process and enhances reprod�cibil-
ity compared with conventional thromboelastography 
[��]. The data obtained whit this new techniq�e are 
contin�o�s�� digital and retrievable for f�rther calc�la-
tions; by processing of data the thrombelastographic 
time co�rse can be transformed into a dynamic veloc-
ity profile of the changes in blood elasticity occ�rring 
d�ring WB clot formation. The instr�ments software is 
�sed to calc�late three new parameters in the assess-
ment of coag�lation dynamic properties. The pattern 
of the new val�es: MaxVel�� t-MaxVel�� AUC�� display a 
remarkable degree of similarity between endogeno�s 
thrombin potential �thrombogram�� and thrombelasto-
graphic model. Therefore the profile of whole blood 
coag�lation by thrombelastography�� as an indirect 
meas�re of thrombin generation�� may provide exten-
sive informations on haemostasis�� not only for the clini-
cal management of bleeding b�t also for thrombophilic 
states [��]. In vivo markers of coag�lation activation 
�prothrombin fragment � + � / F� + ��� and fibrinolysis 
�tiss�e plasminogen activator /t-PA�� correlate very well 
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with ROTEM® clotting time �CT�� and maximal lysis �ML�� 
in a validation of rotation thrombelastography model 
of systemic activation of coag�lation and fibrinolysis 
[��]. TEG has been s�ccessf�lly �sed in clinical setting 
to detect hypercoag�lable states. A postoperative hy-
percoag�lable state�� as revealed by TEG�� was associa-
ted with thrombotic complications in a wide gro�p of 
s�rgical patients followed d�ring postoperative period 
�ntil discharge [�3]. 
fig. 3. Velocity profiles of WB clot formation before s�rgery in neo-
plastic patients and in healthy s�bjects. �a�� Healthy male s�bject 
�red�� and male patient �green�� velocity profile �b��. Healthy female 
s�bject �red�� and female patient �green�� velocity profile 
The correlation between thrombotic complications 
and hypercoag�lability confirms that s�rgical patients 
are at high risk for hypercoag�lability and that this plays 
an important role in the pathogenesis of thrombosis. In 
patients affected by malignant disease�� thrombosis is 
the most freq�ent complication and the second ca�se 
of death [�4]. S�rgical interventions in these patients 
increase the risk of postoperative VTE �approximately 
two-three fold�� in comparison to the risk in non-can-
cer patients �ndergoing the same proced�res. The 
American College of Chest Physicians �ACCP�� has 
stratified patients with malignancy in the highest risk 
category of s�rgical patients and �rged ro�tine throm-
boprophylaxis [��]. Therefore�� especially for high-risk 
patients�� it is strongly desirable to �se a one’s disposal 
test characterized by a higher predictive val�e of the 
thrombotic event. 
Thrombelastography represents a val�able method 
which monitors haemostasis �nder low shear environ-
ment as a whole dynamic process instead of revealing 
information on isolated parts of the different linked path-
ways. Indeed thromboelastometry provides information 
abo�t the whole process of clot formation which res�lts 
from interdependent steps: coag�lation activation�� 
thrombin prod�ction�� fibrin formation and polymeriza-
tion�� platelet activation�� platelet-fibrin interaction.
In concl�sion�� the �se of thrombelastometric 
method  has red�ced the need of s�bstit�tive therapies 
for the clinical management of bleeding problems d�r-
ing major s�rgical interventions �liver transplantations�� 
cardiovasc�lar proced�res�� ne�ros�rgery�� [�6]. Final-
ly�� the a�thors feel that the diagnosis of hypercoag�-
lable state by �sing thromboelastometry�� in patients 
at higher thrombotic risk �especially cancer patients 
d�ring s�rgery���� co�ld provide a rationale for more 
targeted prophylactic antithrombotic treatments. 
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ТромбоэласТография как меТод оценки риска 
Тромбоза при опухолях пищевариТельного ТракТа 
Предпосылки исследования: ��������������� ������ ����� ��������, ����������� �� ���������������� �������������� �         
п�������пух�����й ����п��й, ���������ь�� ���ю���� � ����� п��������� ���д���-��������у�������, ��щ�щ�ющ�х ���ь���� 
�� ��������� �������й ������э������ (VTE) � �������� п��������� ������������. ��� �� ����� �� �д�� �� �������� ��-            
������� ����у������ �� ����� п�������������й �������� � ����� ������� ����������� �������������� �������� у ���д��� 
��д��ь�� �������� п�������. ����������� ����д� ������ ������������ ����� �� ������ю� ����������� ������ � д�������;            
��������, ����д ������э����������� д��� ����������ь �п���������� ������ь �������у ������������ ����� � �����.            
Цель: �п��д����ь, � ����й ���� ���������ь ����у������, �п��д�������й ����д�� ������э�����������, �������� ����������   
��п���������������� ����� у ���ь��х ��������������� п������� п���� х��у���������� ���ш����ь����. Пациенты и мето�
ды: �����д����� 50 ���ь��х ����� п�щ��������ь���� ������ � д��п���������й п����д (27 ���щ��, 23 �у�����, ���д��й           
������� 61,5 ��д� (45–79 ���) � 147 �д�����х д������ (71 �у�����, 76 ���щ��). ���������� ����д ������э�����������,    
���������й �� ������э����������� Г�������, � ��п��ь�������� ����������� ����у������ ����� ROTEM. ���ущ�� д�����   
� ����������� �� 50 ��� ��������й п��д������� � ��д� д��������х п������й ��������� п�� ����������� ��у���� �����. 
Результаты: ����д������ п�������� (п����д ����у������ (CT), п����д ������������ ��у���� (CFT), ��������ь���� п���-          
����ь ��у���� (MCF)) ���ь��х ��������������� п������� ������ � �������ь���. CT у ���ь��х ��������������� п�������            
����������: у ���щ�� �� 50 � (38,3–58,7), у �у���� �� 50 � (42–71,2) vs 51 � (42–59),                 p = 0,1210/53 � ( 42–74,8 ),     p = 0,1975  
� �������ь��й ��упп�. CFT у ����х п�������� ����������: у ���щ�� �� 72 � ( 32–92,4) у �у���� – 80 � (50,2–128,7) vs                    
78 � (62–100), p = 0,0128 / 80 � (59–124,4),         p = 0,9384 � �������ь��й ��упп�. MCF у ���ь��х ��������������� п�������          
����������: у ���щ�� �� 70 �� (59,9–82,5), у �у���� �� 63 �� (56–73,7) vs 69 �� (59–95,8),                 p = 0,9911 / 69 �� (53,6–90),      
p = 0,0135 � �������ь��й ��упп�. �� ���щ�� п��������� ��������� ����� MaxVel ���� ��ш�, ��� у �у����. ����������                 
MaxVel п���ш��� у ����х п��������: у ���щ�� �� 19 ��/100 � (14,3–49,5) у �у���� �� 18 ��/100 � (11–27 ) vs 15 �� /                       
100 � (11,8–22),  p < 0,001 / 13 �� / 100 � (10–21,8),     p <0,001 � �������ь��й ��упп�. ���������ь t-MaxVel п������ у       
���ь��х ��������������� п�������: у ���щ�� – 65 � (48,6–112,8) , у �у���� – 81 � (50,1–135,9) vs 115 � (56,8–166),    
p < 0,001 / 115 � (59,8–180,8), p = 0,0002 � �������ь��й ��упп�. ���������ь AUC у п���ш�� у ���щ�� �� 6451 �� 100         
(5511–8148), у �у���� �� 5984 �� 100 (5119–6899) vs 5778 �� 100 (4998–6655),     p < 0,001 / 5662 �� 100 (4704–6385), 
p = 0.0105. Выводы: � ������� �� д�у��х ����д��, �������ющ�х �������� ��д��ь��х ���п������� ������� ������������            
�����, ����д ������э����������� �������� ���ущ�й п�����ь ������������ ��у���� � ������ ����ь���� ������� � �����������              
������������� �п������� ������ ����������� ��������� у �������������х ���ь��х.       
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